AbbVie (ABBV) Tax Provisions (2012 - 2026)

AbbVie (ABBV) has 15 years of Tax Provisions data on file, last reported at $342.0 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $342.0 million, down 8.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 501.72% YoY), and the FY2025 annual result was $2.4 billion, up 514.74% from the prior year.
• Tax Provisions slipped to $342.0 million in Q1 2026 per ABBV's latest filing, from $853.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $853.0 million in Q4 2025 and troughed at -$2.2 billion in Q4 2024.
• A 5-year average of $322.5 million and a median of $448.0 million in 2022 frame the typical range for Tax Provisions.
• On a YoY basis, Tax Provisions climbed as much as 202.33% in 2024 and fell as far as 678.87% in 2024.
• A 5-year view of Tax Provisions shows it stood at $493.0 million in 2022, then retreated by 21.3% to $388.0 million in 2023, then plunged by 678.87% to -$2.2 billion in 2024, then jumped by 137.98% to $853.0 million in 2025, then slumped by 59.91% to $342.0 million in 2026.
• Business Quant data shows ABBV's Tax Provisions at $342.0 million in Q1 2026, $853.0 million in Q4 2025, and $526.0 million in Q3 2025.